While both classes target the PD‐1/PD‐L1 pathway, emerging evidence suggests that the mechanistic differences are influenced by factors such as PD‐L1/PD‐L2 co‐expression [16], tumor glycosylation patterns [17], and pharmacokinetic properties [18]. The gene discussed is CD274; the disease is neoplasm.